Business
Bioasis to Attend Upcoming Industry Conferences
Bioasis to Attend Upcoming Industry Conferences.
About this update from Bioasis Technologies Inc.
[{"type":"text","content":"\n NEW HAVEN, Conn., Sept. 30, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, announced today that Dr. Deborah Rathjen, Executive Chair, will be attending the following industry conferences: Sachs - 21st Annual Biotech in Europe Forum - Digital ConferenceOctober 7-8, 2021 Dr. Rathjen will be participating as part of the NextGen Neuroscience Panel: Tackling Neuroinflammation & Degeneration. Dr. Rathjen will also present the Bioasis Technologies Inc. corporate presentation and undertake partnering meetings. BIO-Europe DigitalOctober 25-28, 2021 The BIO-Europe Conference brings global biopharma and investment leaders together to build partnerships that facilitate innovation and medical breakthroughs with four days of presentations, productive BIO One-on-One Partnering meetings. Dr. Rathjen will be joined by Bioasis’ business development advisors Shadow Lake Group in partnering meetings. On behalf of the Board of Directors of Bioasis Technologies Inc.Deborah Rathjen, Ph.D., Executive Chair of the Board Follow on:FacebookInstagramLinkedInTwitter BTI-E&P About BioasisBioasis Technologies Inc. is a biopharmaceutical company developing the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The delivery of therapeutics across the blood brain barrier represents the final frontier in treating neurological disorders. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. For more information about the Company, please visit www.bioasis.us. Forward Looking StatementsCertain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-look...